Literature DB >> 20385209

Striatal and white matter predictors of estimated diagnosis for Huntington disease.

Jane S Paulsen1, Peggy C Nopoulos, Elizabeth Aylward, Christopher A Ross, Hans Johnson, Vincent A Magnotta, Andrew Juhl, Ronald K Pierson, James Mills, Douglas Langbehn, Martha Nance.   

Abstract

Previous MRI studies with participants prior to manifest Huntington disease have been conducted in small single-site samples. The current study reports data from a systematic multi-national study during the prodromal period of Huntington disease and examines whether various brain structures make unique predictions about the proximity to manifest disease. MRI scans were acquired from 657 participants enrolled at 1 of 32 PREDICT-HD research sites. Only prodromal Huntington disease participants (those not meeting motor criteria for diagnosis) were included and subgrouped by estimated diagnosis proximity (Near, Mid, and Far) based upon a formula incorporating age and CAG-repeat length. Results show volumes of all three subgroups differed significantly from Controls for total brain tissue, cerebral spinal fluid, white matter, cortical gray matter, thalamus, caudate, and putamen. Total striatal volume demonstrated the largest differences between Controls and all three prodromal subgroups. Cerebral white matter offered additional independent power in the prediction of estimated proximity to diagnosis. In conclusion, this large cross-sectional study shows that changes in brain volume are detectable years to decades prior to estimated motor diagnosis of Huntington disease. This suggests that a clinical trial of a putative neuroprotective agent could begin as much as 15 years prior to estimated motor diagnosis in a cohort of persons at risk for but not meeting clinical motor diagnostic criteria for Huntington disease, and that neuroimaging (striatal and white matter volumes) may be among the best predictors of diagnosis proximity. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20385209      PMCID: PMC2892238          DOI: 10.1016/j.brainresbull.2010.04.003

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  37 in total

1.  Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures.

Authors:  H Diana Rosas; David S Tuch; Nathanael D Hevelone; Alexandra K Zaleta; Mark Vangel; Steven M Hersch; David H Salat
Journal:  Mov Disord       Date:  2006-09       Impact factor: 10.338

2.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

3.  Automatic atlas-based volume estimation of human brain regions from MR images.

Authors:  N C Andreasen; R Rajarethinam; T Cizadlo; S Arndt; V W Swayze; L A Flashman; D S O'Leary; J C Ehrhardt; W T Yuh
Journal:  J Comput Assist Tomogr       Date:  1996 Jan-Feb       Impact factor: 1.826

Review 4.  Trinucleotide instability: a repeating theme in human inherited disorders.

Authors:  J F Gusella; M E MacDonald
Journal:  Annu Rev Med       Date:  1996       Impact factor: 13.739

5.  Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study.

Authors:  Sarah A J Reading; Michael A Yassa; Arnold Bakker; Adam C Dziorny; Lisa M Gourley; Venu Yallapragada; Adam Rosenblatt; Russell L Margolis; Elizabeth H Aylward; Jason Brandt; Susumu Mori; Peter van Zijl; Susan S Bassett; Christopher A Ross
Journal:  Psychiatry Res       Date:  2005-09-30       Impact factor: 3.222

6.  Preparing for preventive clinical trials: the Predict-HD study.

Authors:  Jane S Paulsen; Michael Hayden; Julie C Stout; Douglas R Langbehn; Elizabeth Aylward; Christopher A Ross; Mark Guttman; Martha Nance; Karl Kieburtz; David Oakes; Ira Shoulson; Elise Kayson; Shannon Johnson; Elizabeth Penziner
Journal:  Arch Neurol       Date:  2006-06

7.  Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.

Authors:  E H Aylward; A M Codori; P E Barta; G D Pearlson; G J Harris; J Brandt
Journal:  Arch Neurol       Date:  1996-12

8.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.

Authors:  E H Aylward; J Brandt; A M Codori; R S Mangus; P E Barta; G J Harris
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

9.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

10.  Factors associated with slow progression in Huntington's disease.

Authors:  R H Myers; D S Sax; W J Koroshetz; C Mastromauro; L A Cupples; D K Kiely; F K Pettengill; E D Bird
Journal:  Arch Neurol       Date:  1991-08
View more
  110 in total

1.  Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Authors:  D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale
Journal:  Mov Disord       Date:  2011-09-19       Impact factor: 10.338

2.  Stability of resting fMRI interregional correlations analyzed in subject-native space: a one-year longitudinal study in healthy adults and premanifest Huntington's disease.

Authors:  Tyler M Seibert; D S Adnan Majid; Adam R Aron; Jody Corey-Bloom; James B Brewer
Journal:  Neuroimage       Date:  2011-09-10       Impact factor: 6.556

3.  Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease.

Authors:  J M G van Bergen; J Hua; P G Unschuld; I A L Lim; C K Jones; R L Margolis; C A Ross; P C M van Zijl; X Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-17       Impact factor: 3.825

Review 4.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 5.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

6.  Repeat-associated non-ATG (RAN) translation.

Authors:  John Douglas Cleary; Amrutha Pattamatta; Laura P W Ranum
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

7.  Stable Atlas-based Mapped Prior (STAMP) machine-learning segmentation for multicenter large-scale MRI data.

Authors:  Eun Young Kim; Vincent A Magnotta; Dawei Liu; Hans J Johnson
Journal:  Magn Reson Imaging       Date:  2014-05-09       Impact factor: 2.546

8.  Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease.

Authors:  Deborah L Harrington; Jeffrey D Long; Sally Durgerian; Lyla Mourany; Katherine Koenig; Aaron Bonner-Jackson; Jane S Paulsen; Stephen M Rao
Journal:  Mov Disord       Date:  2016-09-13       Impact factor: 10.338

9.  Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease.

Authors:  Kathryn V Papp; Peter J Snyder; James A Mills; Kevin Duff; Holly J Westervelt; Jeffrey D Long; Spencer Lourens; Jane S Paulsen
Journal:  Arch Clin Neuropsychol       Date:  2012-12-16       Impact factor: 2.813

10.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease.

Authors:  Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero
Journal:  Neurobiol Dis       Date:  2016-09-10       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.